Nothing said here yet.
to join the conversation.
| GREEN ANDREW MSVP, Regulatory and Quality | Sell | 11,480 | $286.7K | Thu, Sep 10 |
| GREEN ANDREW MSVP, Regulatory and Quality | Sell | 1,493 | $38.8K | Thu, Sep 3 |
| GREEN ANDREW MSVP, Regulatory and Quality | Sell | 6,510 | $177.5K | Wed, Sep 2 |
| Mackin James PPresident & CEO | Sell | 70,000 | $2.0M | Wed, Aug 19 |
| Berry Lance AEVP, COO, CFO & Treasurer | Sell | 715 | $20.4K | Fri, Aug 14 |
| GREEN ANDREW MSVP, Regulatory and Quality | Sell | 616 | $17.6K | Fri, Aug 14 |
| Gilbert Cisneros | Buy | $8.0K | Thu, Aug 20 | Fri, Sep 4 |
| Gilbert Cisneros | Buy | $8.0K | Thu, Jul 16 | Fri, Aug 14 |
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its peers.
Investing.com -- Artivion Inc (NYSE:AORT) shares gained 4.2% Tuesday after Jefferies initiated coverage on the cardiovascular medical device maker with a Buy rating and a $31 price target, framing the company as a compelling play on aortic surgery growth.
Artivion has gone through a sharp reset in market expectations, with the share price down heavily over the past year yet still well ahead of where it was three years ago.
On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them.
What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wondering how to approach the situation.
Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount.
Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026.